60 Years after Kefauver: Household income required to buy prescription drugs in the United States and abroad

Using the framework of the historical analysis presented to the Senate Subcommittee on Antitrust and Monopoly, drug prices relative to income in the United States are compared to other Organization for Economic Co-Operation and Development (OECD) countries to improve treatment access and affordability. Countries were selected based on drug price and income data availability and inclusion in the OECD. 40 drugs, 20 brand name and 20 generic, were selected based on revenue sales and prescription volume in 2018. Domestic pricing data included list price, measured by Average Wholesale Price (AWP), and retail price available on GoodRx.com. International drug price data was sourced from publicly available databases on individual country websites. The first analysis illustrates the percentage of household disposable income needed to cover a year supply of a select product. The second analysis illustrates country-specific difference in drug affordability. The last analysis examines the percent of resources an average family, about three persons, would spend on medication in the United Sates if they were a member of different income groups.

基于向参议院反垄断和垄断小组委员会提交的历史分析框架，本数据集将美国药品价格与收入之比与其他经济合作与发展组织（OECD）国家的数据进行比较，旨在提升治疗的可获得性和经济性。数据选取基于药品价格和收入数据的可获得性以及是否包含在OECD内。根据2018年的销售收入和处方量，选取了40种药品，包括20种品牌药和20种通用药。国内定价数据包括清单价格，由平均批发价（AWP）衡量，以及GoodRx.com上可获得的零售价格。国际药品价格数据来源于各国网站上的公开数据库。首次分析展示了覆盖选定产品一年用量所需的家庭可支配收入百分比。第二次分析展示了各国在药品可负担性方面的具体差异。最后，分析考察了一个平均家庭（大约三口之家）在美国，如果其成员属于不同收入群体，将花费多少资源用于药品。